Markets initially responded well to CVS’s Q3 results. In the quarter ... Former Covid supplier champ Moderna (MRNA) closed ...

KP Tissue Inc. (KPT) (TSX: KPT) reports the Q3 2024 financial and operational results of KPT and Kruger Products Inc. (Kruger Products). Kruger ...

Q3 2024 ReportResults in line for Q3 2024 with sales momentum increasing throughout the period and into Q4GIG Software Plc ...

Moderna (MRNA) is up more than +3% after reporting Q3 Covid-19 vaccine revenue of $1.8 billion, which is stronger than the consensus of $1.2 billion. Lyft (LYFT) is up more than +29% after reporting ...

PHILADELPHIA, PA — Carisma Therapeutics Inc. (Nasdaq: CARM) has announced its financial results for the third quarter of 2024 ...

On NVAX's third-quarter earnings call, investors will likely seek updates on management???s ongoing discussions with the FDA ...

Healthcare sector earnings report summary: 14 companies beat profit estimates, with major players like Viatris, Gilead ...

Moderna's stock faces a decline as analysts lower the price target to $90, citing weaker vaccine demand and concerns over ...

Barclays lowered the firm’s price target on Moderna (MRNA) to $111 from $125 and keeps an Overweight rating on the shares. The ...

November 6, 2024Personalis, Inc. misses on earnings expectations. Reported EPS is $-0.64 EPS, expectations were $-0.33.

Moderna ( (MRNA) ) has released its Q3 earnings. Here is a breakdown of the information Moderna presented to its investors. Moderna, Inc. is a ...

Moderna Inc (MRNA) reports $1.9 billion in revenue and outlines future growth strategies despite competitive pressures and ...